JPWO2021147922A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021147922A5 JPWO2021147922A5 JP2022569291A JP2022569291A JPWO2021147922A5 JP WO2021147922 A5 JPWO2021147922 A5 JP WO2021147922A5 JP 2022569291 A JP2022569291 A JP 2022569291A JP 2022569291 A JP2022569291 A JP 2022569291A JP WO2021147922 A5 JPWO2021147922 A5 JP WO2021147922A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- inducible
- skin
- vesicle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 16
- 230000001939 inductive effect Effects 0.000 claims 11
- 239000000126 substance Substances 0.000 claims 5
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims 4
- 230000003712 anti-aging effect Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000004156 Wnt signaling pathway Effects 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- 210000004209 hair Anatomy 0.000 claims 2
- 238000002347 injection Methods 0.000 claims 2
- 239000007924 injection Substances 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 201000004384 Alopecia Diseases 0.000 claims 1
- -1 BIO Chemical compound 0.000 claims 1
- AQGNHMOJWBZFQQ-UHFFFAOYSA-N CT 99021 Chemical compound CC1=CNC(C=2C(=NC(NCCNC=3N=CC(=CC=3)C#N)=NC=2)C=2C(=CC(Cl)=CC=2)Cl)=N1 AQGNHMOJWBZFQQ-UHFFFAOYSA-N 0.000 claims 1
- FABQUVYDAXWUQP-UHFFFAOYSA-N N4-(1,3-benzodioxol-5-ylmethyl)-6-(3-methoxyphenyl)pyrimidine-2,4-diamine Chemical compound COC1=CC=CC(C=2N=C(N)N=C(NCC=3C=C4OCOC4=CC=3)C=2)=C1 FABQUVYDAXWUQP-UHFFFAOYSA-N 0.000 claims 1
- QNVSXXGDAPORNA-UHFFFAOYSA-N Resveratrol Natural products OC1=CC=CC(C=CC=2C=C(O)C(O)=CC=2)=C1 QNVSXXGDAPORNA-UHFFFAOYSA-N 0.000 claims 1
- LUKBXSAWLPMMSZ-OWOJBTEDSA-N Trans-resveratrol Chemical compound C1=CC(O)=CC=C1\C=C\C1=CC(O)=CC(O)=C1 LUKBXSAWLPMMSZ-OWOJBTEDSA-N 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 206010052428 Wound Diseases 0.000 claims 1
- 208000027418 Wounds and injury Diseases 0.000 claims 1
- QHLITPHIARVDJI-UHFFFAOYSA-N [1-[4-(2-naphthalenyl)-2-pyrimidinyl]-4-piperidinyl]methanamine Chemical compound C1CC(CN)CCN1C1=NC=CC(C=2C=C3C=CC=CC3=CC=2)=N1 QHLITPHIARVDJI-UHFFFAOYSA-N 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 230000001640 apoptogenic effect Effects 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 230000002500 effect on skin Effects 0.000 claims 1
- HKSZLNNOFSGOKW-UHFFFAOYSA-N ent-staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(C)O1 HKSZLNNOFSGOKW-UHFFFAOYSA-N 0.000 claims 1
- 210000001808 exosome Anatomy 0.000 claims 1
- 210000004905 finger nail Anatomy 0.000 claims 1
- 230000003660 hair regeneration Effects 0.000 claims 1
- 230000008642 heat stress Effects 0.000 claims 1
- 235000003642 hunger Nutrition 0.000 claims 1
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims 1
- 239000008176 lyophilized powder Substances 0.000 claims 1
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical group CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 1
- 229960003105 metformin Drugs 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 206010033675 panniculitis Diseases 0.000 claims 1
- 229940016667 resveratrol Drugs 0.000 claims 1
- 235000021283 resveratrol Nutrition 0.000 claims 1
- 231100000241 scar Toxicity 0.000 claims 1
- 210000001732 sebaceous gland Anatomy 0.000 claims 1
- 210000001082 somatic cell Anatomy 0.000 claims 1
- 230000037352 starvation stress Effects 0.000 claims 1
- HKSZLNNOFSGOKW-FYTWVXJKSA-N staurosporine Chemical compound C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1[C@H]1C[C@@H](NC)[C@@H](OC)[C@]4(C)O1 HKSZLNNOFSGOKW-FYTWVXJKSA-N 0.000 claims 1
- CGPUWJWCVCFERF-UHFFFAOYSA-N staurosporine Natural products C12=C3N4C5=CC=CC=C5C3=C3CNC(=O)C3=C2C2=CC=CC=C2N1C1CC(NC)C(OC)C4(OC)O1 CGPUWJWCVCFERF-UHFFFAOYSA-N 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 210000004304 subcutaneous tissue Anatomy 0.000 claims 1
- 210000000106 sweat gland Anatomy 0.000 claims 1
- 210000004906 toe nail Anatomy 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 210000003954 umbilical cord Anatomy 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Claims (15)
- 被験体の皮膚または皮膚付属器の疾患または状態を処置するための医薬組成物であって、誘導性小胞を含む、医薬組成物。
- 前記処置は、毛髪再生、傷口癒合、創傷処置、脱毛症処置、瘢痕処置、熱傷処置及び潰瘍処置から選択される、請求項1に記載の医薬組成物。
- 前記皮膚は、表皮組織、真皮組織及び皮下組織から選択され、
前記皮膚付属器は、毛、髪、汗腺、皮脂腺、手の爪及び足の爪から選択される、請求項1または2に記載の医薬組成物。 - 前記誘導性小胞は、幹細胞又は体細胞から選択される細胞に由来する、請求項1から3のいずれか一項に記載の医薬組成物。
- 前記誘導性小胞は、間葉系幹細胞に由来する、請求項1から4のいずれか一項に記載の医薬組成物。
- 前記間葉系幹細胞は、誘導多能性幹細胞、臍帯由来間葉系幹細胞又は骨髄由来間葉系幹細胞である、請求項5に記載の医薬組成物。
- 前記誘導性小胞は、誘導性細胞外小胞、エクソソーム、移動体、微小胞、又はアポトーシス小体である、請求項1から6のいずれか一項に記載の医薬組成物。
- 前記誘導性小胞は、誘導性細胞外小胞である、請求項1から7のいずれか一項に記載の医薬組成物。
- 前記誘導性小胞は、スタウロスポリンの添加、紫外線照射、飢餓法及び熱応力法のうちの1種又は複数種の組み合わせにより調製する、請求項1から8のいずれか一項に記載の医薬組成物。
- 前記誘導性小胞の剤形は、注射用凍結乾燥粉末、注射剤、錠剤、カプセル又は貼付剤である、請求項1から9のいずれか一項に記載の医薬組成物。
- 皮膚薬物又は皮膚ケア物質をさらに含む、請求項1から10のいずれか一項に記載の医薬組成物。
- 前記皮膚薬物及び前記皮膚ケア物質は、前記誘導性小胞に包まれる、請求項11に記載の医薬組成物。
- 老化防止物質又はWntシグナル伝達経路のポジティブレギュレーターをさらに含む、請求項1から12のいずれか一項に記載の医薬組成物。
- 前記老化防止物質は、メトホルミン又はレスベラトロールであり、
前記Wntシグナル伝達経路のポジティブレギュレーターは、Licl、CHIR99021、SB-216763、BIO、Wntアゴニスト及びWAY262611から選択される、請求項13に記載の医薬組成物。 - 前記誘導性小胞と、老化防止物質との比は、(0.5-5)×10 7 個:(0.05-10)mgである、請求項13または14に記載の医薬組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010067658 | 2020-01-20 | ||
CN202010067658.X | 2020-01-20 | ||
CN202010066154.6 | 2020-01-20 | ||
CN202010066154 | 2020-01-20 | ||
PCT/CN2021/072937 WO2021147922A1 (zh) | 2020-01-20 | 2021-01-20 | 细胞外囊泡及其在皮肤产品的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023513394A JP2023513394A (ja) | 2023-03-30 |
JPWO2021147922A5 true JPWO2021147922A5 (ja) | 2024-01-29 |
Family
ID=76811282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022569291A Pending JP2023513394A (ja) | 2020-01-20 | 2021-01-20 | 細胞外小胞及びその皮膚製品における使用 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20230084480A1 (ja) |
JP (1) | JP2023513394A (ja) |
CN (1) | CN113134015B (ja) |
WO (1) | WO2021147922A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115725493A (zh) * | 2021-08-26 | 2023-03-03 | 中山大学 | 一种力学性囊泡的制备方法 |
CN113876928B (zh) * | 2021-10-22 | 2022-08-05 | 北京赛尔再生医学生物科技有限公司 | 成纤维细胞外囊泡制备及在美容和药品中的应用 |
WO2023123216A1 (zh) * | 2021-12-30 | 2023-07-06 | 中山大学 | 囊泡在制备治疗肺部疾病的药物中的应用 |
WO2023123215A1 (zh) * | 2021-12-30 | 2023-07-06 | 医微细胞生物技术(广州)有限公司 | 细胞外囊泡的应用 |
WO2023155146A1 (en) * | 2022-02-18 | 2023-08-24 | Tsinghua University | Methods for regulating mitochondria homeostasis |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BR112017018744B1 (pt) * | 2015-03-05 | 2021-10-26 | Lubrizol Advanced Materials, Inc | Uso de um extrato de fermento, composição cosmética, e, método para o tratamento e/ou cuidado, não terapêutico cosmético da pele |
KR20160110232A (ko) * | 2015-03-11 | 2016-09-21 | 주식회사 엠디헬스케어 | 유산균 유래 세포밖 소포체를 유효성분으로 포함하는 염증질환의 예방 또는 치료용 조성물 |
KR102394638B1 (ko) * | 2015-09-30 | 2022-05-09 | (주)아모레퍼시픽 | 유산균 유래의 세포외 소낭을 포함하는 탈모 방지 또는 육모 촉진용 조성물 |
CN107893050A (zh) * | 2017-10-17 | 2018-04-10 | 杜水果 | 一种细胞外囊泡及其制备方法和用途 |
KR102015116B1 (ko) * | 2018-05-04 | 2019-10-21 | (주)메디톡스 | 표적 단백질을 코딩하는 폴리뉴클레오티드를 포함하는 재조합 미생물로부터 유래한 세포외 소낭 및 그의 용도 |
CN111494417B (zh) * | 2020-02-10 | 2024-04-09 | 寇晓星 | 诱导性细胞外囊泡在制备治疗肿瘤药物中的应用 |
-
2021
- 2021-01-20 CN CN202110076177.XA patent/CN113134015B/zh active Active
- 2021-01-20 WO PCT/CN2021/072937 patent/WO2021147922A1/zh active Application Filing
- 2021-01-20 US US17/793,833 patent/US20230084480A1/en active Pending
- 2021-01-20 JP JP2022569291A patent/JP2023513394A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20210113620A1 (en) | Platelet-rich plasma composition for tissue repair and regeneration | |
Block et al. | Emerging therapies for scar prevention | |
US9782438B2 (en) | Method of promoting hair growth by administration of BFGF | |
EA029443B1 (ru) | Фармацевтическая композиция на основе лизата тромбоцитов | |
JP2019535417A (ja) | 皮膚の美容外観 | |
Herman et al. | Skin care during the menopause period: noninvasive procedures of beauty studies | |
Hyakusoku et al. | Color atlas of burn reconstructive surgery | |
Levy et al. | Comparison of injection comfort of a new category of cohesive hyaluronic acid filler with preincorporated lidocaine and a hyaluronic acid filler alone | |
JPWO2021147922A5 (ja) | ||
Honardar et al. | The effect of chitosan-based gel on second degree burn wounds | |
US11045503B2 (en) | Pharmaceutical composition for preventing, treating and curing rosacea, comprising snail slime, chamomile and propolis | |
Miller-Kobisher et al. | Epidermal growth factor in aesthetics and regenerative medicine: systematic review | |
Martínez et al. | Hair-follicle transplant into chronic ulcers: a new graft concept | |
WO2015107237A1 (es) | Formulación cosmética de uso tópico con capacidad de regeneración dérmica, epidérmica y antiarrugas | |
Safonov | Atlas of scar treatment and correction | |
Kabala-Dzik et al. | Influence of honey-balm on the rate of scare formation during experimental burn wound healing in pigs | |
Eryani et al. | The Healing Effect of Adipose-derived Stem Cell Conditioned Medium on Burn Wound Model. | |
RU2805144C1 (ru) | Рекомбинантный ангиогенин в косметических и фармацевтических композициях | |
Svolacchia et al. | Off-label use of a medium-high molecular weight, isotonic and sterile hyaluronic acid in aesthetic medicine: cases report | |
Mora et al. | Allogenic Lysate Platelet on Deep Second Degree Burns | |
Yuan et al. | A case report and discussion of Lichen myxedematosus. | |
Galęba et al. | Achievements of modern aesthetic medicine as seen from the perspective of “20th World Congress of Aesthetic Medicine in Miami” | |
Loder et al. | Skin grafting | |
RU2242964C1 (ru) | Косметическое средство для стимулирования роста волос | |
Safonov et al. | Atrophic scars and stretch marks |